Dare Bioscience
DARE
15 hedge funds and large institutions have $899K invested in Dare Bioscience in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
4% more capital invested
Capital invested by funds: $864K → $899K (+$35.3K)
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.17% less ownership
Funds ownership: 0.73% → 0.56% (-0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$64.9K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$61.3K |
| 3 |
Renaissance Technologies
New York
|
+$53.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$38.8K |
| 5 |
VF
Virtu Financial
New York
|
+$37.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$395K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$18.7K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$11K |
| 4 |
Barclays
London,
United Kingdom
|
-$8.89K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PVMCV
1
Polaris Venture Management Co V
Boston,
Massachusetts
| $382K | – | – | – |
|
|
PAM
2
Panagora Asset Management
Boston,
Massachusetts
| $110K | +$61.3K | +4,588 | +140% |
|
|
VF
3
Virtu Financial
New York
| $86K | +$37.9K | +2,834 | +86% |
|
|
4
Renaissance Technologies
New York
| $75K | +$53.5K | +4,008 | +302% |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $68K | +$64.9K | +4,858 | New |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $66K | -$18.7K | -1,397 | -23% |
|
|
BFM
7
Boothbay Fund Management
New York
| $41K | – | – | – |
|
|
8
Citadel Advisors
Miami,
Florida
| $41K | +$38.8K | +2,906 | New |
|
9
Northern Trust
Chicago,
Illinois
| $12K | +$11.6K | +872 | New |
|
|
10
Barclays
London,
United Kingdom
| $9K | -$8.89K | -666 | -50% |
|
11
UBS Group
Zurich,
Switzerland
| $7K | +$5.94K | +445 | +1,011% |
|
|
AWA
12
Artemis Wealth Advisors
New York
| $1.03K | – | – | – |
|
13
BlackRock
New York
| $1K | – | – | – |
|
|
CH
14
CVI Holdings
Wilmington,
Delaware
| – | -$395K | -39,305 | Closed |
|
|
TSS
15
Two Sigma Securities
New York
| – | -$11K | -1,133 | Closed |
|
DARE Hedge Fund Activity: Q2 2018 in Review
15 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q2 2018, worth a combined $899K — up 4.1% from $864K a quarter earlier.
Fund positioning in DARE was balanced in Q2 2018: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $64.9K. The largest seller was CVI Holdings, exiting entirely with an estimated $395K sold.
- 15 institutional investors held Dare Bioscience (DARE) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $899K of Dare Bioscience stock for Q2 2018, up 4.1% quarter-over-quarter.
- 3 funds opened new Dare Bioscience positions in Q2 2018 and 3 closed out, a net change of 0 holders.
- The largest Dare Bioscience buyer in Q2 2018 was Geode Capital Management, an estimated $64.9K added.
- The largest Dare Bioscience seller in Q2 2018 was CVI Holdings, an estimated $395K sold.
Based on aggregated 13F filings for Q2 2018.